Insilico Medicine vs West Pharmaceutical Services
Side-by-side comparison of AI visibility scores, market position, and capabilities
Insilico Medicine (HKEX: 3696) raised $293M, posted $56.2M revenue in 2025, and inked a $2.75B Eli Lilly deal in 2026 using generative AI to discover drug targets in cancer and CNS.
About
Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in Hong Kong and New York, the company has built AI platforms utilizing deep generative models, reinforcement learning, and transformers to discover novel drug targets and generate molecular structures with desired properties. Its pipeline spans cancer, fibrosis, CNS diseases, infectious diseases, autoimmune conditions, and aging-related diseases.
West Pharmaceutical Services (WST) reported ~$3.0B revenue in FY2024. Designs packaging components and delivery systems for injectable drugs — critical for vaccine and biologic drug manufacturing. HQ: Exton, PA.
About
West Pharmaceutical Services, Inc. is the global leader in packaging components and delivery systems for injectable medications, designing and manufacturing the stoppers, closures, caps, and drug delivery systems that seal vials, syringes, and cartridges containing vaccines, biologics, and injectable drugs. Every major pharmaceutical company and biologic manufacturer relies on West's containment solutions — the small rubber stopper sealing an mRNA vaccine vial or insulin cartridge is almost certainly a West product.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.